Peptides Combination

Home > Peptides > Peptides Combination

Peptide Combinations 0.5mg CJC with DAC + 0.5mg Hexarelin + 1mg Ipamorelin

0.5mg CJC with DAC
0.5mg Hexarelin
1mg Ipamorelin
INQUIRE NOW!

Description

CJC-1295


CJC-1295 is a long acting GHRH analog. Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin, is a 44-amino acid peptide hormone produced in the hypothalamus by the arcuate nucleus. GHRH stimulates growth hormone (GH) secretion from the pituitary. GHRH is released in a pulsatile manner, stimulating pulsatile release of GH respectively.

The active portion of this GRF or GHRH peptide can be found as a 29 amino acid long peptide and is appropriately named GHRH1-29. This pulsatile release of various peptides is due to the negative feedback loop that is part of the hGH axis and controls the amount of hGH that your body produces to keep it in a homeostatic environment. Despite the effectiveness of GHRH to stimulate growth hormone release there are a number of problems associated with using it in vivo. The most noteworthy problem is the half life of the peptide, which has been shown to be ~7 minutes using advanced HPLC technologies that have proven to be very accurate. The reason for this relatively short half life is due to an enzyme called dipeptidylaminopeptidase IV (DPP-IV), which has a high affinity for the amino acids Ala and Pro and in the case of GHRH it cleaves the 1 and 2 positions that consist of Tyr-Ala, creating GHRH3-29, an inactive form of the peptide. To prevent the problems associated with natural GHRH, pharmaceutical companies looked at new ways to increase the half life and bioavailability of these smaller peptides with technologies that work far different than other technologies, such as PEGylation. 
CJC-1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days! Bioconjugation is a relatively newer technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin. Once the CJC-1295 molecule has attached itself to albumin, it is given an extended half life and bioavailability thanks to the albumin preventing enzymatic degredation and kidney excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo and over 90% was stabilized after subcutaneous injection. This means that you get more of what you paid for working for you. There was no DPP-IV degredation observed on CJC -1295 in any of the various experiments conducted.


Hexarelin:


Hexarelin is in the category of drugs known as GH secretagogues. This category of drugs includes GHRP-2, GHRP-6, Ipamorelin, and Hexarelin. Its primary function is to stimulate the pituitary gland to produce more growth hormone. Like the other GHRPs, it has a 2-fold mechanism of action, in that it causes an increase in GH through amplifying the natural growth hormone releasing hormone (GHRH) signal transduction pathway, as well as by suppressing the actions of Somatostatin.

Hexarelin, on a mcg per mcg basis, is the most potent of the GHRP’s for GH release. However, Hexarelin administration will quickly lead to desensitization when used at effective dosages, which makes it less than ideal for long-term use. This limitation has led to a decrease in popularity among users of GH peptides, with GHRP-2 and Ipamorelin leading the pack in the area of long-term effectiveness. However, these limitations do not mean Hexarelin is worthless. On the contrary, Hexarelin can be added to other GHRP’s (such as GHRP-2 & Ipamorelin) in lower dosages, in order to elicit further elevations in GH without incurring the desensitization that commonly presents itself when using Hex alone at peak effective dosages.

Recommendations for use:

* Hexarelin should be administered on an empty stomach. No food should be consumed at least 15-20 minutes post-inject, if maximum GH release is desired.
* The average dosing range is between 100-150 mcg per inject. Dosing frequency is between 1-4X per day.
* In order to elicit maximal elevations in GH, Hexarelin should be combined with a GHRH, such as ModGRF1-29 (also known as CJC1295 w/o dac).

* In order to avoid the rapid desensitization that typically accompanies Hexarelin use, it can be added to GHRP-2 and/or Ipamorelin at a dosage of 100 mcg 2-3 X per day. If this practice is limited to every other day usage, Hex can be used long-term, while increasing GH levels beyond what is normally experienced when using average doses of GHRP-2 or Ipamorelin.


Ipamorelin


Ipamorelin is in the category of drugs known as GH secretagogues. This category of drugs includes GHRP-2, GHRP-6, Ipamorelin, and Hexarelin. Its primary function is to stimulate the pituitary gland to produce more growth hormone. Like the other GHRPs, it has a 2-fold mechanism of action, in that it causes an increase in GH through amplifying the natural growth hormone releasing hormone (GHRH) signal transduction pathway, as well as by suppressing the actions of Somatostatin.

Ipamorelin is a 3rd generation GHRP which displays great selectivity in its actions. Ipamorelin will not lead to any degree of appetite stimulation, will not affect prolactin or cortisol, and is used solely for GH release. On a mcg to mcg basis, its strength is comparable to GHRP-6, but unlike GHRP-6, it can be dosed much higher, resulting in potentially greater elevations in GH. Similar to GHRP-2, IPA has no ceiling dose. Therefore, as the dosage of IPA is titrated upward, GH release will continue to rise accordingly. Ipamorelin has developed a reputation as the “cleanest” of the GHRP’s and rightfully so.

Common benefits of GH (Ipamorelin) include:

* Decreases in body fat
* An increase in lean mass
* Increased collagen production
* Improved sleep
* Increased cellular repair
* An increase in IGF-1
* Increases in bone density

Common side effects of GH (Ipamorelin) include:

* Water retention
* Tightness and/or carpel tunnel-like symptoms
* Numbness and tingling in the extremities
* A decrease in insulin sensitivity
* Tiredness

Recommendations for use:

* Ipamorelin should be administered on an empty stomach. No food should be consumed at least 15-20 minutes post-inject, if maximum GH release is desired.

* The average dosing range is between 100-2,000 mcg per inject. Dosing frequency is as little as 3X per week when mega-dosing…and up to 4X per day when using lower dosages.

* In order to elicit maximal elevations in GH, IPA should be combined with a GHRH, such as ModGRF1-29 (also known as CJC1295 w/o dac).


Description

Write Your Own Review


Bella
Email
TOP